about
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agentsThe regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic inventionSirtuins: molecular traffic lights in the crossroad of oxidative stress, chromatin remodeling, and transcriptionHDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulationFE65 binds Teashirt, inhibiting expression of the primate-specific caspase-4The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice.Negative and positive regulation of gene expression by mouse histone deacetylase 1Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and FutureDietary epigenetics in cancer and agingEpigenetics in breast cancer: what's new?Metabiotics: One Step ahead of Probiotics; an Insight into Mechanisms Involved in Anticancerous Effect in Colorectal CancerNovel functional view of the crocidolite asbestos-treated A549 human lung epithelial transcriptome reveals an intricate network of pathways with opposing functionsThe role of T‑box genes in the tumorigenesis and progression of cancer (Review)Quercetin enhances the antitumor activity of trichostatin A through upregulation of p53 protein expression in vitro and in vivoExploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation AssaysEffects of Sodium Butyrate Treatment on Histone Modifications and the Expression of Genes Related to Epigenetic Regulatory Mechanisms and Immune Response in European Sea Bass (Dicentrarchus Labrax) Fed a Plant-Based DietVorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cellsPreclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas.Limited proteolysis of human histone deacetylase 1A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer.Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome.Oral and intraperitoneal administration of quercetin decreased lymphocyte DNA damage and plasma lipid peroxidation induced by TSA in vivo.Histone deacetylase inhibitors induce apoptosis in human eosinophils and neutrophils.The G1 phase arrest and apoptosis by intrinsic pathway induced by valproic acid inhibit proliferation of BGC-823 gastric carcinoma cells.HDAC Inhibitors Disrupt Programmed Resistance to Apoptosis During Drosophila Development.Melding a New 3-Dimensional Agarose Colony Assay with the E(max) Model to Determine the Effects of Drug Combinations on Cancer Cells.Genomic analysis of individual differences in ethanol drinking: evidence for non-genetic factors in C57BL/6 mice.Ferritin H induction by histone deacetylase inhibitors.A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors.RUNX3 is involved in caspase-3-dependent apoptosis induced by a combination of 5-aza-CdR and TSA in leukaemia cell lines.Epigenetics and chromatin remodeling play a role in lung diseaseSomatic nucleus reprogramming is significantly improved by m-carboxycinnamic acid bishydroxamide, a histone deacetylase inhibitor.Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.Histone deacetylase: a potential therapeutic target for fibrotic disordersHistone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies.Histone deacetylase inhibitors: discovery and development as anticancer agents.[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice.The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells.Genome-wide screening for genes associated with valproic acid sensitivity in fission yeast
P2860
Q21198868-DABBAE34-8A9B-4690-AD6E-91BB8F0C5533Q21245733-AAA1D7F6-B5F5-4A61-91AD-13B910EEA6F3Q21296795-A8AD3A2B-3C53-4821-A9A5-AF5DAD069D4BQ24310722-04025BC4-C753-4F5B-B490-2C5D88AC599EQ24312011-6458735F-2B1B-4A88-AEA8-CFB348A05FEEQ24656405-7DA943A8-7994-4A9F-A63A-BE717EA76FA4Q24672508-D9427C45-87D3-40DB-BA3C-810E47E99DBEQ26746934-DF20F013-7271-4FEA-AF44-E7ECAE936EC1Q26858886-78E7F502-7774-4541-89CE-EEF4EECAD06FQ26991779-36FDCDE9-D161-4DB3-8FCC-1363C29C321DQ28077783-A3261F00-73FD-4B8C-A02D-6294E0D9CA97Q28385588-8D3AAB2B-C783-4975-AFE4-AEC590E5A5A0Q28468370-0BB5F18C-F74E-46E0-86E7-705577BD5477Q28485136-5F655E09-9770-42D5-92E0-70095780F081Q28550025-8E797007-9F15-46EA-BAF4-F5F32DD7927EQ28553330-6FEA16A7-2F61-43B0-BC14-4045B63CFDB1Q28743758-3E62F48E-2273-427D-917C-6F54BB6AA6ECQ30459589-AF98F1F7-4E41-4D39-A18F-B445D0BB765AQ33259445-000AE9A4-F55A-4728-B41E-08E8137A5521Q33384180-36FD217A-FDAA-441D-B3F0-C9F299AD6DD3Q33429707-4D9809F1-BBC7-46E9-B871-825C26E85DAAQ33597498-8EB10342-3CE7-47A3-9A88-A8C697A1D540Q33737214-87E9F7CF-0E38-4287-B981-390648040B34Q33757575-6D745FE2-BF59-49A0-9519-26CBA69C7337Q33807699-B90819B5-5ED2-4A61-BDF3-DAA2A5421557Q33827019-5201C0A3-F607-40D8-8F17-40273340EE57Q33940849-CEEFF9B3-80FF-4783-A942-1090BC5F9105Q34034477-A991F7B2-1839-4D85-997F-91C3CFC53E2BQ34099365-90A11A41-F326-4872-9223-28822F7E51E0Q34104638-042BDFC0-BE69-41B3-81B3-86BFA39C7C92Q34126445-9E4E6F51-79ED-4EB3-A0A1-EB6951C1EE39Q34155461-739D0743-3715-4AC4-848D-542095A4E20EQ34171631-4851CDD2-9BD7-4B81-B250-D93D992EC5BBQ34257607-B67AE64D-4744-4986-8AAB-A58EE733B1E7Q34399444-D1C24AB2-05B4-4FA4-8CD3-806DC51A10DDQ34470150-F1526E95-1281-4304-B2B6-AE075F7E9738Q34645445-E1C2CC8B-F135-40E5-9B52-C25095A54646Q34725589-9AD57DE1-F7D3-4FCD-84A4-A523FF877415Q34771550-D4A51BB1-824B-4746-82EE-72A161E67ACEQ34828049-7D0517B4-1109-49EC-9A83-3FE2114F939B
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Prospects: histone deacetylase inhibitors.
@ast
Prospects: histone deacetylase inhibitors.
@en
type
label
Prospects: histone deacetylase inhibitors.
@ast
Prospects: histone deacetylase inhibitors.
@en
prefLabel
Prospects: histone deacetylase inhibitors.
@ast
Prospects: histone deacetylase inhibitors.
@en
P356
P1476
Prospects: histone deacetylase inhibitors.
@en
P2093
Milos Dokmanovic
Paul A Marks
P2860
P304
P356
10.1002/JCB.20532
P577
2005-10-01T00:00:00Z